1. Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function
- Author
-
Borin MT, Lo A, Barnes CN, Pendyala S, and Bourdet DL
- Subjects
Liver disease ,kidney disease ,chronic obstructive pulmonary disease ,long-acting muscarinic antagonist ,LAMA ,revefenacin ,Diseases of the respiratory system ,RC705-779 - Abstract
Marie T Borin,1 Arthur Lo,2 Chris N Barnes,3 Srikanth Pendyala,4 David L Bourdet2 1Department of Clinical and Translational Pharmacology, Theravance Biopharma US, Inc., South San Francisco, CA, USA; 2Department of Drug Metabolism and Pharmacokinetics, Theravance Biopharma US, Inc., South San Francisco, CA, USA; 3Department of Biostatistics, Theravance Biopharma US, Inc., South San Francisco, CA, USA; 4Department of Clinical Development, Inflammation and Immunology, Theravance Biopharma US, Inc., South San Francisco, CA, USACorrespondence: David L BourdetDepartment of Drug Metabolism and Pharmacokinetics, Theravance Biopharma US, Inc., 901 Gateway Boulevard, South San Francisco, CA 94080, USATel +1 650 808 3755Email dbourdet@theravance.comPurpose: Revefenacin, a long-acting muscarinic antagonist for nebulization, has been shown to improve lung function in patients with chronic obstructive pulmonary disease. Here we report pharmacokinetic (PK) and safety results from two multicenter, open-label, single-dose trials evaluating revefenacin in subjects with severe renal impairment (NCT02578082) and moderate hepatic impairment (NCT02581592).Subjects and methods: The renal impairment trial enrolled subjects with normal renal function and severe renal impairment (estimated glomerular filtration rate
- Published
- 2019